AN2 Therapeutics, Inc. reports

Company location: Menlo Park, CA
Fiscal year end: 31 December

AN2 Therapeutics, Inc. has filed 373 SEC EDGAR filings since 24 Sep 2021

Filter by type:
10-K
10-Q
8-K
SC13G

SEC filing history

Showing 126-150 of 373 matching filings.

Per page

25

Current page

6

SCHEDULE 13G/A File 005-93617

SCHEDULE 13G/A filing

Filing date: 14 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SCHEDULE 13G/A File 005-93617

SCHEDULE 13G/A filing

Filing date: 14 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SCHEDULE 13G/A File 005-93617

SCHEDULE 13G/A filing

Filing date: 14 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SCHEDULE 13G/A File 005-93617

SCHEDULE 13G/A filing

Filing date: 13 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SCHEDULE 13G/A File 005-93617

SCHEDULE 13G/A filing

Filing date: 13 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 07 Jan 2025
Reporting date: 03 Jan 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 07 Jan 2025
Reporting date: 03 Jan 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 07 Jan 2025
Reporting date: 03 Jan 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 07 Jan 2025
Reporting date: 03 Jan 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 23 Dec 2024
Reporting date: 19 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 23 Dec 2024
Reporting date: 19 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 23 Dec 2024
Reporting date: 19 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 23 Dec 2024
Reporting date: 19 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 23 Dec 2024
Reporting date: 19 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 10 Dec 2024
Reporting date: 06 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 27 Nov 2024
Reporting date: 26 Nov 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 27 Nov 2024
Reporting date: 27 Nov 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 21 Nov 2024
Reporting date: 19 Nov 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 20 Nov 2024
Reporting date: 18 Nov 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4

Filing date: 18 Nov 2024
Reporting date: 18 Nov 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-93617

AMENDMENT NO. 2 TO SCHEDULE 13G

Filing date: 14 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-93617

SC 13G/A

Filing date: 14 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-93617

SC 13G/A

Filing date: 13 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

10-Q File 001-41331

10-Q

Filing date: 13 Nov 2024
Reporting date: 30 Sep 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-41331

8-K

Filing date: 13 Nov 2024
Reporting date: 13 Nov 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .